Home / Companies / Immuneel Therapeutics

Immuneel Therapeutics

Biotechnology (Cell Therapy)Bengaluru, Karnataka, India

Immuneel Therapeutics is an Indian cell and gene therapy company developing CAR-T treatments for blood cancers. Its lead product, Qartemi, is an indigenously developed CD19-targeted CAR-T therapy approved in India for relapsed or refractory B-cell lymphoma.

1StartupFox story
2019Founded
Biotechnology(Cell Therapy)Sector
Jun 2026Latest coverage

Funding

Immuneel Therapeutics has raised $12M across 1 disclosed round, most recently a Series B in Jun 2026.

$12MRaised
Series BLatest round · Jun 2026
1Event
Chart appears once 2 more funding rounds are recorded — below that a chart shows less than the table does.
Jun 2026Series B$12M (₹100 crore)Singularity AMC, Rainmatter, Eight Roads Ventures, F-Prime CapitalStartupFox ↗

Investor roster

Every disclosed backer and how often they've written a cheque — repeat names are the strongest conviction signal on the cap table.

New · Latest leadSingularity AMC1 round · 2026
Eight Roads Ventures1 round · 2026
F-Prime Capital1 round · 2026
Rainmatter1 round · 2026
Aggregated automatically from the disclosed rounds above.

Leadership

KMKiran Mazumdar-ShawCo-founder · Founder, BioconSMSiddhartha MukherjeeCo-founder · Oncologist

The Immuneel Therapeutics journey

2019 · founded
Founded in Bengaluru by Siddhartha Mukherjee, Kiran Mazumdar-Shaw, Arun Anand.
Jun 2026 · funding
Series B — $12M, led by Singularity AMC.
Jun 2026 · milestone
Scaling Qartemi — India's first indigenously developed and approved CAR-T therapy — with GMP expansion and entry into APAC and the Middle East. ↗

The rest of Immuneel Therapeutics's profile is free

Every funding round with its source, verified financials, leadership and the full journey timeline — sign in once and it stays unlocked.

One tap. No newsletter unless you ask for it.

Latest on Immuneel Therapeutics

Funding
Immuneel Therapeutics Raises Over ₹100 Crore in Series B Round to Scale Indigenous CAR-T Cancer Therapy
8 JUN 2026 · 2 MIN READ

Also in Health & Bio

Hoola HealthHealthcare / Paediatric ClinicsBiodimensionLife Sciences / BiofabricationCARPL.aiHealthtech / Medical Imaging AIGPS RenewablesClean Energy / Biofuels

Frequently Asked

What is Immuneel Therapeutics?

Immuneel Therapeutics is an Indian cell and gene therapy company developing CAR-T treatments for blood cancers. Its lead product, Qartemi, is an indigenously developed CD19-targeted CAR-T therapy approved in India for relapsed or refractory B-cell lymphoma.

Who founded Immuneel Therapeutics?

Immuneel Therapeutics's founders and leadership on record at StartupFox are Siddhartha Mukherjee, Kiran Mazumdar-Shaw and Arun Anand.

How much funding has Immuneel Therapeutics raised?

Immuneel Therapeutics has raised $12M across 1 disclosed round. The most recent was a $12M Series B in Jun 2026.

Who are Immuneel Therapeutics's investors?

Disclosed investors in Immuneel Therapeutics include Singularity AMC, Rainmatter, Eight Roads Ventures, F-Prime Capital.

What is the latest news on Immuneel Therapeutics?

The most recent StartupFox coverage is “Immuneel Therapeutics Raises Over ₹100 Crore in Series B Round to Scale Indigenous CAR-T Cancer Therapy” (8 June 2026). All stories are listed on this page.

Sources & updates

This profile is compiled by the StartupFox desk from company announcements, regulatory and exchange filings (RoC/MCA, NSE/BSE) and our own reporting. 1 of 1 funding round links to a named source.

Last updated
How we verify
Sourcing standards
Spot an error?
Request a correction